Odyssey Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Odyssey Therapeutics, Inc. (ODTX) reported Increase Decrease In Operating Lease Liability of -$2.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Odyssey Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.25M.
- Odyssey Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.23M.
- Odyssey Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$843.00K.
- Odyssey Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$1.06M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month |
|---|---|---|
| 2026-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.48M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$1.23M 10-Q · filed 2026-06-17 | |
| 2025-06-30 | -$843.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.91M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$1.06M 10-Q · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |